Patient characteristics

Image
Top banner braf

BEACON CRC: The first phase 3 trial to exclusively study patients with BRAFV600E-mutant mCRC.

Patient characteristics were well balanced accross arms

Baseline characteristics3

  BRAFTOVI + cetuximab
     (n=220)
FOLFIRI + cetuximab
     or irinotecan + cetuximab
(n=221)
Age    
Median (range) 61 (30-91) years 60 (27-91) years
Sex, % (n)    
Male 52% (115) 43% (94)
Female 48% (105) 57% (127)
ECOG PS, % (n)    
0 51% (112) 49% (108)
1 47% (104) 51% (113)
Location   of primary tumour, % (n)  
Right side 50% (110) 54% (119)
Left side 38% (83) 31% (68)
Organs   with metastases, % (n)  
≥3 47% (103) 44% (98)
Liver metastases, % (n)    
Present 61% (134) 58% (128)
Previous   lines of therapy, % (n)  
1 66% (146) 66% (145)
2 34% (74) 34% (76)
MSI, % (n)    
Abnormal, high 9% (19) 5% (12)

The majority of patients (66%) in the BRAFTOVI + cetuximab arm received only 1 prior systemic therapy.3

HealthCare Professionals​

This is an international website for BRAFTOVI dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that:

I am Healthcare Professional outside the US and I have read the information above​. 

Patients

This is an international website for BRAFTOVI dedicated to Healthcare professionals.

I am a patient outside the US​